Ubrogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used as a pharmaceutical raw material for the acute management of migraine with or without aura.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1374248-77-7
Atogepant
pharmaceutical raw material
Rimegepant
pharmaceutical raw material
Rimegepant sulfate
pharmaceutical raw material
3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
pharmaceutical raw material
Ribociclib succinate
pharmaceutical raw material
Rociletinib
pharmaceutical raw material
Trilaciclib
pharmaceutical raw material
(3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DDOOFTLHJSMHLN-ZQHRPCGSSA-N
C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6